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and formoterol in reversing methacholine-induced 
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Department of Respiratory Diseases, De Wevev Hospital, Heerlen, The Netherlands 
This single-centre, randomized, double-blind, double-dummy four-way cross-over study in 24 moderately severe 
asthmatic patients compared the speed of onset of recommended doses of salbutamol (200,~g) and formoterol 
(12pg) delivered by metered-dose inhaler in reversing the bronchoconstriction induced by a cumulative dose of 
methacholine to produce a 20% decrease (PDZO) in forced expiratory volume in 1 s (FEV,). 
Specific airway conductance (SGAW) and airway resistance (RAW) were measured in baseline condition, 
immediately after challenge and 0.5, 15, 3, 5, 10, 15, 30, 60 min and every hour up to 4 h after inhalation of the trial 
drug. FEV, was measured in baseline condition, after challenge and 15, 30 and 60 min and then every 30 min up to 
4 h after inhalation of the study drug. The primary efficacy parameter was the change in SGAW. 
Salbutamol produced a two-fold increase in SGAW within 4 min and a maximum increase after 79.3 min. 
Formoterol produced a two-fold increase in SGAW after 5 min and a maximum increase after 119.6 min. Changes in 
SGAW were slightly, but consistently, higher during the first 2 h after inhalation of salbutamol, both in absolute 
values and as a percentage of the maximum response. Differences were significant at 10, 15 and 30 min time points. 
There was no significant difference between the maximum values of SGAW after the two drugs. Changes in RAW and 
FEV, reflected the differences in SGAW. 
It was concluded that in methacholine-induced bronchoconstriction both formoterol and salbutamol have a very 
fast onset of action, achieving prechallenge values of SGAW within 3 min, salbutamol being slightly faster than 
formoterol. 
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Introduction 
Short-acting inhaled /&-agonists such as salbutamol are 
widely used for the treatment of acute asthma attacks. 
Salbutamol acts quickly to relieve bronchoconstriction but 
its duration of action is relatively short (4-6 h) (1). The 
number of puffs of salbutamol used by a patient gives a 
good indication of the degree of actual asthma control. 
Long-acting j&-agonists such as salmeterol and formot- 
erol have a bronchodilatory effect that lasts for up to 12 h 
(2-6). They are recommended as asthma maintenance 
therapy in international guidelines and have been reserved 
by regulatory authorities for this purpose. 
An important characteristic of an acute treatment is the 
speed of onset and the time to relief of symptoms. In vitro 
studies using isolated guinea-pig trachea have generated 
conflicting results: a study of the effect of drugs on isolated 
preparations contracted with carbachol found the onsets of 
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action of formoterol and salbutamol to be similar (7). 
However, a study on electrically stimulated preparations 
found that for salbutamol the time to attain 50% of the half 
maximal response was about 3 min whereas for formoterol 
the time was 8 min (8). A number of clinical studies in 
situations of spontaneous bronchoconstriction have dem- 
onstrated that both drugs have rapid onsets of action 
(3,4,0 
A shortcoming of these studies however, is the inter- 
individual variability in the degree of bronchoconstriction, 
with the consequence that it is difficult to study effects of 
different treatments in a controlled manner. It is preferable 
to standardize the level of bronchoconstriction, and this has 
been done using methacholine challenge (9), which closely 
mimics an attack of asthma. A number of studies have 
assessed the speeds of onset of action of bronchodilator 
drugs using this methodology but only one study (10) 
directly compared salbutamol and formoterol. This placebo- 
controlled study, which compared two doses of formoterol 
with salbutamol, concluded that both drugs had a rapid 
onset of action, with benefits apparent within 2 min. Assess- 
ment of airway function however, was based on measure- 
ment of FEV,, which, being effort dependent, is a less 
sensitive procedure than the measurement of specific airway 
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conductance (SGAW) (I 1,12), as was used in the present 
study. The rationale for the present study therefore was to 
compare the speeds of onset of recommended doses of 
salbutamol (200 pug) and formoterol (12 ,ug) following 
methacholine challenge, using the most sensitive methodol- 
ogy available for assessment of changes in airway calibre. 
Methods 
PATIENTS 
Male and non-pregnant female patients with moderately 
severe asthma aged between 18 and 60 years, who were able 
to use a metered-dose inhaler correctly, had measurable 
airway responsiveness [cumulative dose of methacholine 
less than 1600 pg needed to produce a 20% decrease (PD& 
in FEV,], had a baseline FEV, of less than 80% of the 
predicted value and demonstrated a reversibility in FEV, 
more than 15% of the baseline value following inhalation of 
2OOpg of salbutamol were included in the study. Patients 
were excluded if they had changed their regular asthma 
therapy, suffered from a respiratory tract infection or had 
an exacerbation of their asthma during the 4 weeks prior to 
the study. Patients were also excluded if they were being 
treated with any P-receptor antagonist or if they had taken 
any other experimental drug in the 30 days prior to the 
study. 
The patients abstained from long-acting inhaled 
&-agonists, oral /&-agonists, theophyllines or antihista- 
mines at least 24 h prior to the methacholine challenge tests 
and had to abstain from short-acting inhaled &agonists 
for 12 h. Ipratropium bromide, other anticholinergic drugs 
or astemizole were not permitted at any time during the 
study. The following drugs were permitted if taken in a 
stable dose: nedocromil sodium, cromolyn sodium, anti- 
histamines and oral and/or inhaled corticosteroids up to a 
maximum of 800 pg day - ’ (400 pg day- i of fluticasone 
propionate). The study was approved by the local medical 
ethics committee and informed consent was obtained from 
all patients. The study was conducted according to the 
Declaration of Helsinki as modified by the Hong Kong 
Amendment 1989. 
STUDY DESIGN 
This was a single-centre, randomized; double-blind, double- 
dummy, four-period, four-treatment cross-over study. 
There being no data available on the variability of response 
of RAW, SGAW and FEV, following treatment with 
salbutamol or formoterol after methacholine challenge, the 
sample size was fixed for practical considerations as 24 
evaluable patients. Each eligible patient was to receive a 
single dose of each of four treatments via a metered-dose 
inhaler on 4 different study days in random sequence 
ordered according to a randomly allocated row of a 4 x 4 
William’s Latin Square. The four treatments consisted of 
two pairs as detailed below: 
Treatment 1A: salbutamol200 pg followed immediately by 
formoterol placebo. 
Treatment 1B: formoterol placebo followed immediately by 
salbutamol 200,~g. 
Treatment 2A: formoterol 12,~g followed immediately by 
salbutamol placebo. 
Treatment 2B: salbutamol placebo followed by formoterol 
12Kz. 
Thus the treatments within each pair where the same but 
the orders were reversed. This allowed for the possibility 
that the speeds of onset of action might be very rapid so 
that order of delivery of active treatment (before or after 
placebo) might have an important impact on the measured 
speed of response. 
Patients made four study visits (visits 2-5) to the clinic, 
each being within 2-10 days of the preceding visit. The first 
of these visits was l-7 days following an initial visit (visit 1) 
at which patient eligibility was determined. During visits 
2-5 RAW, SGAW and FEV, were measured in baseline 
condition. Methacholine was administered by dosimeter 
according to a validated method (13) in doubling cumula- 
tive doses at 5-min intervals until FEV, had fallen by 20% 
or more. The challenge was then stopped and the patient 
monitored until FEV, had stabilized for at least 3 min. 
Postchallenge values of RAW, SGAW and FEV, were 
recorded and patients received one of four treatments 
according to the randomization sequence via a Volumatica 
attached to a metered-dose inhaler. 
RAW and SGAW were measured again in the same way 
0.5, 1.5, 3, 5: 10, 15, 30, 60 min and every hour up to 4 h 
after inhalation of the study drugs. RAW and SGAW were 
measured in a pressure-compensated integrated flow 
plethysmograph (2800 Autobox: Sensormedics) as the 
chord slopes between inspiratory and expiratory flow of 
05 1 s ~ i at a respiratory rate of O-5 Hz. Means of nine 
measurements were reported. Because of the limitation 
in time during the first 5 min three measurements were 
performed at each timepoint. 
FEV, was measured 15, 30 and 60 min after treatment 
and then every 30 min up to 4 h. The highest value of 
three manoeuvres was retained. As a deep inspiration, 
necessary for the FEV, manoeuvre, may influence 
bronchial tone over several min, response during the first 
15 min after inhalation of the drug was only assessed by the 
measurement of SGAW. 
All adverse events occurring during the study were 
recorded. 
STATISTICAL ANALYSIS 
The speed of onset of action of study treatment following 
methacholine challenge was characterized by the pattern of 
change in SGAW, RAW, and FEV,. Time to attain maxi- 
mum value; and the area under the response curve at 5 min, 
following challenge were compared. In addition, mean 
values of SGAW, RAW and FEV, at each timepoint were 
compared. Comparisons of times taken to achieve specified 
levels of each of these variables (e.g. time to reach twice 
postchallenge levels of SGAW) were planned but could not 
be made due to lack of power. In the event, there was no 
evidence that order of delivery of active treatment had any 
impact on speed of onset of action, the time delay between 
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TABLE 1. Characteristics of the 24 patients in the study 
Gender F/M 6/18 
Age (years) 521t6 
Height (cm) 171 Zt 8 
Weight (kg) 78 * 16 
FEV, at baseline (1) 2.00 f 0.56 
FEV, at baseline (% pred) 62 rt 14 
Reversibility (% baseline FEV,) 39 LIT 17 
SGAW at baseline (kPa - ’ s ~ r) 0.45 zt 0.17 
PD,, FEV, median &g methacholine) 43 (range O-1493) 
Values are presented as mean f SD. F, female; M, male; 
FEV,, forced expiratory value in 1 s; % pred, percentage of 
predicted value; SGAW, specific airway conductance; PD,, 
FEN, dose of methacholine causing a fall in FEV, of 20% 
of baseline value. 
treatments (active-placebo pair) being much smaller than 
the time taken to achieve significant recovery following 
challenge. Accordingly, patient response was characterized 
as the average over pairs of study days where the same 
active treatment was given. Comparisons between treat- 
ments were made using analysis of covariance (ANCOVA) 
controlling for postchallenge baseline values, as well as 
study period and patient differences. There were no grounds 
a priori for expecting carry-over treatment effect given the 
relatively short half-life of the two study drugs compared to 
the relatively long interval between study days. Accordingly 
we did not allow for the possible effect of carry-over 
in analysis. The analysis was carried out using SASa 
proc GLM. Values of SGAW, RAW and FEV, were log- 
transformed prior to analysis. 
Results 
DEMOGRAPHICS AND BASELINE 
MEASUREMENTS 
Twenty-seven patients were enrolled in the study. Three of 
these patients withdrew from the study prior to randomiz- 
ation and are therefore not included in the intent-to-treat 
analysis. The demographic data and baseline lung function 
of the 24 patients who participated in the study are given in 
Table 1. Twenty-three were receiving asthma medication, 
mostly an inhaled ,&-agonist (23) and an inhaled steroid 
(18). All patients randomized to receive treatment com- 
pleted the methacholine challenge on four occasions as 
required by the protocol. Premethacholine challenge values 
of SGAW, RAW and FEV, (Table 2) and PD,, FEV, 
remained relatively stable throughout the study. 
SPECIFIC AIRWAY CONDUCTANCE (SGAW) 
Levels of SGAW were slightly, but consistently, higher 
following treatment with salbutamol as compared to for- 
moterol at all timepoints over the first 2 h. Comparing 
treatments at each timepoint in turn, this difference only 
TABLE 2. Mean ( f SD) values of SGAW, RAW and FEV, 
immediately before methacholine challenge 
SGAW FEV, 
Treatment (kPaa’s-r) (kPa:‘ss’) (1) 
Salbutamol 0.47 + 0.18 0.47 * 0.15 1.91 f 0.49 
Formoterol 0.44 25 0.17 0.51 It 0.17 1.87 f 0.53 
10 15 20 25 30 
Time (min) 
FIG. 1. Mean values of specific airway conductance 
(SGAW) during the first 30 min after salbutamol (04) 
and formoterol (0- 4). 
0.21 “‘I ““N ““‘I 1”““’ 
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Time (min) 
FIG. 2. Mean values of specific airway conductance 
(SGAW) over 4 h after salbutamol (04) and formoterol 
(O- 4). 
reached statistical significance at 10 and 15 min after treat- 
ment (P40.05) (Figs 1, 2). 
However, comparisons of AUC, which represents a 
weighed average of SGAW values, show how the consistent 
direction of the treatment differences accumulates to give a 
stronger overall level of statistical evidence. By 15 min 
the AUC difference was statistically significant (P=O.O4) 
and gave an estimated difference in mean SGAW levels 
of 0.59 kPapl s-l for salbutamol compared to 
0.55 kPa- ’ s- ’ for formoterol over this period. 
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EIG. 3. Mean difference (95% CI) in SGAW after salbuta- 
mol or formoterol, expressed as a percentage of the maxi- 
mum achieved and adjusted for differences in SGAW 
following methacholine challenge and for the effects of 
patient and visit. 
From Fig. 1 it can be derived that salbutamol produced a 
two-fold increase in SGAW within 4 min, compared to 5 min 
for formoterol. Both salbutamol and formoterol achieved 
premethacholine SGAW values within 3 min. There was no 
significant difference between the maximum values for 
SGAW after inhalation of the two drugs, with increases of 
184% after salbutamol and 176% after formoterol. The 
mean time taken for salbutamol to induce a maximal 
increase in SGAW was 79.3 min compared to 119.6 min 
after formoterol [P<O.Ol, 95% confidence interval (CI) 
- 64.6- - 16.11. As the curves were fairly flat, the actual 
maximum occurred relatively late. After 4 h SGAW level 
was higher following formoterol than after salbutamol. 
When the data were expressed alternatively at each 
timepoint as a percentage of the maximum increase in 
SGAW, salbutamol showed a small, but consistent benefit 
over the first 2 h after administration of the drugs, being 
statistically significant 10 and 30 min after inhalation 
(WO.05) (Fig. 3). 
SPECIFIC AIRWAY RESISTANCE (RAW) 
The differences in RAW between salbutamol and formoterol 
reflected the differences in SGAW; RAW was approximately 
5% and 2% lower following salbutamol when expressed in 
absolute terms over the first 60 min and as a percentage of 
the maximum decrease over the first 120 min. For the latter 
comparison; this reached statistical significance after 60 min 
(P<O.O5). Furthermore, the time taken for salbutamol to 
induce a maximal decrease in RAW occurred significantly 
earlier than with formoterol. The mean maximal decreases 
in RAW occurred 69.6 min after salbutamol compared to 
112.8 min after formoterol (P<O.Ol; 95% CI - 7@4- 
- 15.9). The time taken to achieve a two-fold decrease in 
RAW was statistically significantly faster for salbutamol 
(l-0.05). 
B,,,,,l,,l,,i,,,,,,,,,,, 
1.40 
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FIG. 4. Mean values of forced expiratory volume in 1 s 
(FEV,) over 4 h after salbutamol ( ) and formoterol 
(O- -0). 
FORCED EXPIRATORY VOLUME IN 1 S (FEV,) 
FEV, values were also greater (approximately 2%) follow- 
ing salbutamol over the first 2 h when expressed as a 
percentage of the maximal increase although there was no 
difference between the two treatments in terms of absolute 
FEV, values (Fig. 4). 
TOLERABILITY 
Both drugs were well tolerated and no adverse events were 
reported. 
This study compared the onsets of action of the recom- 
mended dose of salbutamol(200 pg) and formoterol(12,~g) 
in reversing methacholine-induced bronchoconstriction. 
The results suggest that the onset of action of salbutamol is 
slightly faster than that of formoterol. This was demon- 
strated in several ways. Changes in SGAW and RAW were 
slightly but consistently higher during the first 2 h after 
inhalation of salbutamol, both in absolute values and as 
Fercentages of the maximum response. Furthermore, both 
the time to reach a specified increase in SGAW and the time 
to attaining a maximum level of SGAW were shorter after 
salbutamol than after formoterol. 
Four clinical studies have compared the time courses of 
the bronchodilatory effects of salbutamol and formoterol. 
Derom et al (3), Wallin et al (4) and Van Noord et al (6) 
used SGAW as the pharmacodynamic endpoint whilst Beach 
et al (10) used FEV,. Measurements of SGAW offer two 
advantages. First, they are a more sensitive index of 
changes in airway calibre than FEV, (1!,14). Second, they 
avoid a deep inspiration, necessary for the FEV, 
manoeuvre, which has variable effects on the magnitude 
and direction of change in airway calibre in asthmatic 
subjects, depending on changes in the relative degree of 
hysteresis of airways and parenchyma (15). The studies 
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which used SGAW as the endpoint produced conflicting 
results: Wallin et al (4) and Van Noord et al (6) suggested 
that the two drugs had similar onset times whilst in the 
study by Derom et al (3) salbutamol had a faster onset of 
action when the data were expressed either as a percentage 
of the maximum response or as time to maximum response. 
It can be argued that these studies were not performed 
under conditions which simulate acute bronchoconstriction 
and it is difficult to study spontaneously occurring 
bronchoconstriction repeatedly in a controlled way (9). The 
study by Beach et al (lo), which did use a controlled 
bronchoconstriction model, concluded that salbutamol and 
formoterol at both 12pg and 24pg produced marked 
bronchodilator effects within 2 min and reached a peak 
within 10 min but detected no significant differences 
between the treatments. However, as discussed above the 
study used the relatively insensitive and less appropiate 
FEV, as an endpoint. 
Furthermore, when looking at the shape of the curves of 
formoterol 12pg and salbutamol200 pg, salbutamol is also 
consistently higher than formoterol 12pg, which is in line 
with our findings. The present study is the first to compare 
salbutamol and formoterol using SGAW as the endpoint 
and using methacholine challenge to induce a standardized 
level of bronchoconstriction. 
In designing the present study other challenge tests were 
considered: although exercise and allergen are less artificial 
and more closely analogous to naturally occurring 
bronchoconstriction, methacholine challenge was selected 
because of its greater sensitivity and the fact that it has been 
shown to be predictive of the allergen response (16). 
Measurements were performed when the fall in FEV, was 
at least 20% of the baseline value after methacholine and 
had reached a plateau for at least 3 min. Cartier et al (17) 
demonstrated that the mean duration of this plateau phase 
was 75 min (range 12-150). This suggests that measure- 
ments during the first 1.5 min purely reflect the effects of the 
drugs investigated, whereas later spontaneous recovery of 
bronchoconstriction can interfere. However, by comparing 
the two time-response curves the latter effect is eliminated. 
Malo et al (18) concluded that after a methacholine test 
the response to an inhaled &agonist was less than in a 
situation of spontaneous airway obstruction. Merkus et al 
(19) found that after histamine challenge and subsequent 
spontaneous recovery a higher dose of salbutamol was 
required to obtain the same bronchodilatation as on the 
control day. These authors suggested that the effects of 
bronchial challenge on the airway wall could limit or delay 
the bronchodilator response. Our study indicates that the 
onset of action of /&-agonists after methacholine-induced 
bronchoconstriction is not affected and seems similar to a 
situation of spontaneous airway obstruction. 
The present study, in common with previous studies, has 
demonstrated that differences between the time courses of 
salbutamol and formoterol are small, statistically significant 
differences between them being achieved only at 10 and 
15 min after treatment. This is the first study to assess the 
effect of treatment within the first min and furthermore a 
total of four assessments of lung function were made within 
the first 5 min. We believe that the fact that salbutamol 
begins to demonstrate a more rapid effect than formoterol 
during this time period, even if the difference is small, can be 
important to a patient suffering from an acute attack of 
bronchoconstriction. Using SGAW as an endpoint the study 
demonstrated a difference in time of 1 min to a twofold 
increase (4 min salbutamol vs 5 min formoterol). 
We conclude that in methacholine-induced broncho- 
constriction, which can be considered as a model of an 
acute asthma attack, both salbutamol and formoterol have 
a very rapid onset of action, salbutamol being slightly 
faster. 
At present, in most guidelines (20) short-acting /&- 
agonists are indicated for episodic bronchoconstriction and 
long-acting &agonists are recommended as maintenance 
therapy when standard doses of inhaled corticosteroids fail 
to achieve control of asthma (17). We believe that the 
present study is supportive of this strategy. 
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